SCHEMBL22364249

SCHEMBL22364249

Cn1c(O)c(C(N)=Nc2ccc(-c3cnn[nH]3)cc2)c(=O)n(C)c1=O

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
XDH P47989 4/20 0.64
MAPT P10636 6/20 0.41
LMNA P02545 5/20 0.41
HTT P42858 4/20 0.41
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
HSP90AA1 P07900 1/20 0.39
GAA P10253 2/20 0.38
USP2 O75604 1/20 0.38
HSD17B10 Q99714 3/20 0.36
TSHR P16473 2/20 0.36
KMT2A Q03164 4/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CREBBP Q92793 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22381452 0.78 XDH (0.65) XDHMAPTLMNAHTTALDH1A1
SCHEMBL22364248 0.76 XDH (0.54) XDHMAPTLMNAHTTALDH1A1
SCHEMBL24222108 0.71 XDH (0.53) XDHKMT2AMEN1RAB9A
SCHEMBL24222220 0.69 XDH (0.45) XDHMAPTALDH1A1GAAHPGD
SCHEMBL22381443 0.64 XDH (0.49) XDH
SCHEMBL22364244 0.64 XDH (0.45) XDHMAPTLMNAHTTGAA
SCHEMBL22381444 0.63 XDH (0.67) XDHALDH1A1KDM4E
SCHEMBL13411815 0.63 POLB (0.33) ALDH1A1SMN1; SMN2USP2KMT2AMEN1
SCHEMBL22381451 0.62 XDH (0.43) XDH
SCHEMBL1187135 0.61 RPS6KA3 (0.42) MAPTSMN1; SMN2USP2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220024900-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2022-01-27 US disclosed
US-11168075-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-11-09 US disclosed
US-20200347034-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2020-11-05 US disclosed
US-10759784-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2020-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347034-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, PON1 XDH 1/4885MAPT 3322/4885LMNA 3213/4885
US-20220024900-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, PON1 XDH 1/4885MAPT 3322/4885LMNA 3213/4885
US-11168075-B2 Compounds and their use for reducing uric acid levels XDH, OAT, PON1 XDH 1/4885MAPT 3322/4885LMNA 3213/4885
US-10759784-B2 Compounds and their use for reducing uric acid levels XDH, OAT, PON1 XDH 1/4885MAPT 3322/4885LMNA 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.